FORT MYERS, Fla. — NeoGenomics has agreed to pay approximately $9.8 million plus interest to resolve a federal investigation into consulting services the oncology diagnostics company provided to certain healthcare providers.
The civil settlement was reached with the Department of Justice on behalf of the Office of Inspector General of the U.S. Department of Health and Human Services. The investigation concerned consulting arrangements connected to laboratory testing services offered through NeoGenomics’ Laboratory Collaboration Initiative.
NeoGenomics voluntarily disclosed the matter to the inspector general’s office in November 2021 and cooperated with the government’s investigation, according to the settlement agreement.
The company will pay $9,813,260, along with annual interest of 4.25% calculated from Jan. 16, 2026. NeoGenomics previously reported that it had set aside $11.2 million to cover potential damages and other liabilities related to the investigation.
“We are pleased to resolve this legacy matter,” Chief Executive Officer Tony Zook said. “The resolution of this voluntary disclosure will allow the Company to continue moving forward with its vision and commitment to advancing personalized cancer care.”
The settlement does not constitute an admission of liability by NeoGenomics. It also does not represent a concession by the federal government that its claims lacked merit.
